|
1
|
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
|
Eur J Cancer
|
2010
|
1.08
|
|
2
|
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
|
J Clin Oncol
|
2010
|
1.03
|
|
3
|
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
|
BMC Res Notes
|
2012
|
0.90
|
|
4
|
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
|
Clin Cancer Res
|
2011
|
0.90
|
|
5
|
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
|
BioDrugs
|
2013
|
0.88
|